Department of Biomedical Engineering, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, People's Republic of China.
Int J Nanomedicine. 2022 May 16;17:2191-2202. doi: 10.2147/IJN.S358469. eCollection 2022.
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic progenitor cells, and the AML cells are differentiation retarded which results in the hyperproliferation of those malignant tumor cells. To stop the uncontrollable proliferation, inducing the AML cell differentiation is one highly expected therapy because it can bring relatively low systematic side effects compared to conventional chemotherapies; however, there are few options of inductive therapeutics in the clinical applications so far. This study aims to investigate the differentiation-induction effects of lab-developed hydrophilic nanocrystals of AsS (ee-AsS).
In this work, ee-AsS was applied upon a refractory mouse model co-expressing AML1-ETO and HyC-KIT as well as a related human AML cell line, Kasumi-1, to investigate whether the nanocrystals can break the retardation of differentiation and drive the cells undergo apoptosis.
It was shown that ee-AsS induced the upregulation of surface markers CD11b, CD235a, and CD41a, which indicate granulocytic, erythroid, and megakaryocytic differentiation respectively, leading to the multiple-lineage differentiation and post-differentiation apoptosis, and the inhibition of histone deacetylase activity was largely involved with the differentiation-induction effects. In the AML mice, orally administered ee-AsS increased the level of Ter119, CD11b, and CD41 in bone marrow-derived leukemia cells while reducing the percentage of leukemic cells in the bone marrow. Also, ee-AsS improved the hemogram and relieved the hepatomegaly and splenomegaly of the AML mice. As a result, the survival of the AML mice was significantly prolonged. Importantly, ee-AsS did not cause acute or chronic toxicity in healthy mice.
In conclusion, ee-AsS induced effective and multiple-lineage differentiation and apoptosis of AML cells in the refractory AML mouse model and cell line, suggesting that it holds promising potential as a novel inductive agent in differentiation therapy of AML.
急性髓系白血病(AML)是一种造血祖细胞的异质性克隆疾病,AML 细胞分化受阻,导致这些恶性肿瘤细胞过度增殖。为了阻止这种不可控的增殖,诱导 AML 细胞分化是一种非常有前景的治疗方法,因为与传统化疗相比,它的系统副作用相对较低;然而,到目前为止,临床应用中诱导治疗的选择很少。本研究旨在探讨我们实验室开发的 AsS 亲水性纳米晶体(ee-AsS)的分化诱导作用。
在这项工作中,ee-AsS 被应用于表达 AML1-ETO 和 HyC-KIT 的难治性小鼠模型以及相关的人 AML 细胞系 Kasumi-1,以研究纳米晶体是否能打破分化的阻滞并促使细胞发生凋亡。
结果表明,ee-AsS 诱导表面标志物 CD11b、CD235a 和 CD41a 的上调,分别表示粒细胞、红细胞和巨核细胞分化,导致多系分化和分化后凋亡,组蛋白去乙酰化酶活性的抑制在很大程度上与分化诱导作用有关。在 AML 小鼠中,口服给予 ee-AsS 增加了骨髓源性白血病细胞中 Ter119、CD11b 和 CD41 的水平,同时降低了骨髓中白血病细胞的百分比。此外,ee-AsS 改善了血象,缓解了 AML 小鼠的肝脾肿大。结果,AML 小鼠的存活率显著延长。重要的是,ee-AsS 未在健康小鼠中引起急性或慢性毒性。
总之,ee-AsS 在难治性 AML 小鼠模型和细胞系中诱导 AML 细胞有效且多系分化和凋亡,表明其作为 AML 分化治疗的新型诱导剂具有很大的潜力。